The Desmoid Tumor Research Foundation

March 2022

The efficacy of low-power cumulative high-intensity focused ultrasound treatment for recurrent desmoid tumor

Author Information

Zhong X (1), Hu X (1), Zhao P (2), Wang Y (2), Fang XF (1), Shen J (3), Shen H (1), Yuan Y (1)

(1) Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. (2) College of Metrology and Measurement Engineering, China Jiliang University, Hangzhou, China. (3) Zhejiang University-University of Edinburgh (ZJU-UOE) Institute, Zhejiang University School of Medicine, Haining, China.

Publication

Cancer Med

Summary

Background: Desmoid tumors are rare neoplasms that are locally invasive. However, optimal treatment strategies for recurrent desmoid tumors remain controversial. High-intensity focused ultrasound (HIFU) has been reported as a noninvasive modality for treating recurrent desmoid tumors. However, its efficacy against massive desmoid tumors or those with complex anatomies remains unclear. Methods: We developed a new therapeutic strategy called low-power cumulative HIFU and applied it to treat recurrent desmoid tumors. Results: We retrospectively collected data from 91 patients with recurrent desmoid tumors who underwent low-power cumulative HIFU treatment after surgical treatment failure. The mean ablation proportion of the HIFU treatment was 69.5%, and the objective response rate was 47.3%. The 5-year estimated progression-free survival rate for these patients was 69.3%. Conclusion: Low-power cumulative HIFU treatment could achieve significant efficacy and long-term control of recurrent desmoid tumors.

View Abstract